Comparative genomic assessment of novel broad-spectrum targets for antibacterial drugs

Comparative and Functional Genomics

Volumn 5, Issue 4, 2004, Pages 304-327

  White, Thomas A ^a   Kell, Douglas B ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antibacterial; Antibiotics; Antimicrobial; Bioinformatics; Comparative genomics; Genomics; Pathogen; Virulence

Indexed keywords

ALANINE RACEMASE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BACITRACIN; BETA LACTAM ANTIBIOTIC; CARBOXYPEPTIDASE; CHLORAMPHENICOL; CYCLOSERINE; DIHYDROFOLATE REDUCTASE; DNA TOPOISOMERASE IV; FOLIC ACID; FOSFOMYCIN; FUSIDIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLYCOPEPTIDE; INITIATION FACTOR; MACROLIDE; METHYLTRANSFERASE; OXAZOLIDINONE DERIVATIVE; PEPTIDOGLYCAN; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; RIFAMYCIN; RNA POLYMERASE; STREPTOGRAMIN DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRANSFER RNA; TRIMETHOPRIM; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ARTICLE; BIOINFORMATICS; COMPARATIVE STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; ESCHERICHIA COLI; EUKARYOTE; GENETIC CONSERVATION; GENOMICS; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ONLINE SYSTEM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS AUREUS; TISSUE DISTRIBUTION;

ESCHERICHIA COLI; EUKARYOTA; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 3042647771     PISSN: 15316912     EISSN: None     Source Type: Journal    
DOI: 10.1002/cfg.411     Document Type: Article

References (78)

1. Ahn HJ, Kim HW, Yoon HJ, et al. 2003. Crystal structure of tRNA(m1G37)methyltransferase: insights into tRNA recognition. EMBO J 22: 2593-2603.
2. Alksne LE. 2002. Virulence as a target for antimicrobial chemotherapy. Expert Opin Investig Drugs 11: 1149-1159.
3. Allsop A, Illingworth R. 2002. The impact of genomics and related technologies on the search for new antibiotics. J Appl Microbiol 92: 7-12.
4. Allsop AE. 1998. New antibiotic discovery, novel screens, novel targets and impact of microbial genomics. Curr Opin Microbiol 1: 530-534.
5. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215: 403-410.
6. Altschul SF, Madden TL, Schaffer AA. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acid Res 25: 3389-3402.
7. Bauer E, Kohavi R. 1999. An empirical comparison of voting classification algorithms: bagging, boosting and variants. Machine Learning 36: 105-139.
8. Bouhss A, Mengin-Lecreulx D, Blanot D, van Heijenoort J, Parquet C. 1997. Invariant amino acids in the Mur peptide synthetases of bacterial peptidoglycan synthesis and their modification by site-directed mutagenesis in the UDP-MurNAc:L-alanine ligase from Escherichia coli. Biochemistry 36: 11556-11563.
9. Brunder W, Khan AS, Hacker J, Karch H. 2001. Novel type of fimbriae encoded by the large plasmid of sorbitol-fermenting enterohemorrhagic Escherichia coli O157:H(-). Infect Immun 69: 4447-4457.
10. Buysse JM. 2001. The role of genomics in antibacterial target discovery. Curr Med Chem 8: 1713-1726.
11. Chittum HS, Champney WS. 1995. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol 30: 273-279.
12. Chopra I, Hesse L, O'Neill AJ. 2002. Exploiting current understanding of antibiotic action for discovery of new drugs. J Appl Microbiol 92(suppl): 4S- 15S.
13. Coello Coello CA, van Veldhuizen DA, Lamont GB. 2002. Evolutionary Algorithms for Solving Multi-objective Problems. Kluwer Academic: Dordrecht.
14. Cummings HS, Hershey JW. 1994. Translation initiation factor IF1 is essential for cell viability in Escherichia coli. J Bacteriol 176: 198-205.
15. Dahlquist KD, Puglisi JD. 2000. Interaction of translation initiation factor IF1 with the E. coli ribosomal A site. J Mol Biol 299: 1-15.
16. Dasgupta P, Chakrabarti PP, DeSarkar SC. 1999. Multiobjective Heuristic Search. Vieweg: Braunschweig.
17. Davies J. 1994. Inactivation of antibiotics and the dissemination of resistance genes. Science 264: 375-382.
18. Deb K. 2001. Multi-objective Optimization Using Evolutionary Algorithms. Wiley: Chichester.
19. Dietterich TG. 2000. An experimental comparison of three methods for constructing ensembles of decision trees: bagging, boosting, and randomization. Machine Learning 40: 139-157.
20. Dougherty TJ, Barrett JF, Pucci MJ. 2002. Microbial genomics and novel antibiotic discovery: new technology to search for new drugs. Curr Pharm Des 8: 1119-1135.
21. Dunman PM, Murphy E, Haney S, et al. 2001. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 183: 7341-7353.
22. Egebjerg J, Douthwaite S, Garrett RA. 1989. Antibiotic interactions at the GTPase-associated centre within Escherichia coli 23S rRNA. EMBO J 8: 607-611.
23. El Zoeiby A, Sanschagrin F, Levesque RC. 2003. Structure and function of the Mur enzymes: development of novel inhibitors. Mol Microbiol 47: 1-12.
24. Fell DA. 1996. Understanding the Control of Metabolism. Portland Press: London.
25. Forsyth RA, Haselbeck RJ, Ohlsen KL, et al. 2002. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 43: 1387-1400.
26. Giaever G, Shoemaker DD, Jones TW, et al. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nature Genet 21: 278-283.
27. Gillies D. 1996. Artificial Intelligence and Scientific Method. Oxford University Press: Oxford.
28. Glass JI, Belanger AE, Robertson GT. 2002. Streptococcus pneumoniae as a genomics platform for broad-spectrum antibiotic discovery. Curr Opin Microbiol 5: 338-342.
29. Gribskov M. 1992. Translational initiation factors IF-1 and eIF-2αshare an RNA-binding motif with prokaryotic ribosomal protein S1 and polynucleotide phosphorylase. Gene 119: 107-111.
30. Hancock REW, Knowles D. 1998. Are we approaching the end of the antibiotic era? Curr Opin Microbiol 1: 493-494.
31. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ. 2002. Genomics in anti-infective drug discovery - getting to endgame. Curr Pharm Des 8: 1099-1118.
32. Hastie T, Tibshirani R, Friedman J. 2001. The Elements of Statistical Learning: Data Mining, Inference and Prediction. Springer-Verlag: Berlin.
33. Heinemann JA. 1999. How antibiotics cause antibiotic resistance. Drug Discov Today 4: 72-79.
34. Heinrich R, Schuster S. 1996. The Regulation of Cellular Systems. Chapman & Hall: London.
35. Hoffmaster AR, Koehler TM. 1999. Control of virulence gene expression in Bacillus anthracis. J Appl Microbiol 87: 279-281.
36. Hopkins AL, Groom CR. 2002. The druggable genome. Nat Rev Drug Discov 1: 727-730.
37. Inoue R, Kaito C, Tanabe M, et al. 2001. Genetic identification of two distinct DNA polymerases, DnaE and PolC, that are essential for chromosomal DNA replication in Staphylococcus aureus. Mol Genet Genom 266: 564-571.
38. Isaacson RE. 2002. Genomics and the prospects for the discovery of new targets for antibacterial and antifungal agents. Curr Pharm Des 8: 1091-1098.
39. Ji Y. 2002. The role of genomics in the discovery of novel targets for antibiotic therapy. Pharmacogenomics 3: 315-323.
40. Kell DB, Oliver SG. 2004. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26: 99-105.
41. Kell DB, Westerhoff HV. 1986. Metabolic control theory: its role in microbiology and biotechnology. FEMS Microbiol Rev 39: 305-320.
42. Knowles DJ, King F. 1998. The impact of bacterial genomics on antibacterial discovery. Adv Exp Med Biol 456: 183-195.
43. Knowles JD, Watson RA, Corne DW. 2001. Reducing local optima in single-objective problems by multi-objectivization. In Proceedings of the 1st International Conference on Evolutionary Multi-criterion Optimization (EMO'01), E. Zitzler, et al. (eds). Springer: Berlin; 269-283.
44. Kobayashi K, Ehrlich SD, Albertini A, et al. 2003. Essential Bacillus subtilis genes. Proc Natl Acad Sci USA 100: 4678-4683.
45. Koehler TM. 2002. Bacillus anthracis genetics and virulence gene regulation. Curr Top Microbiol Immunol 271: 143-164.
46. Kornder JD. 2002. Streptomycin revisited: molecular action in the microbial cell. Med Hypoth 58: 34-46.
47. Kumar S, Tamura K, Jakobsen IB, Nei M. 2001. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17: 1244-1245.
48. Lin AH, Murray RW, Vidmar TJ, Marotti KR. 1997. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 41: 2127-2131.
49. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
50. Marmor S, Petersen CP, Reck F, et al. 2001. Biochemical characterization of a phosphinate inhibitor of Escherichia coli MurC. Biochemistry 40: 12207-12214.
51. McDevitt D, Rosenberg M. 2001. Exploiting genomics to discover new antibiotics. Trends Microbiol 9: 611-617.
52. Mitchell TM. 1997. Machine Learning. McGraw Hill: London.
53. Mjolsness E, DeCoste D. 2001. Machine learning for science: state of the art and future prospects. Science 293: 2051-2055.
54. Neu HC, Gootz TD. 1996. Antimicrobial chemotherapy. In Medical Microbiology, Baron S (ed.). University of Texas Medical Branch.
55. Oneyama C, Nakano H, Sharma SV. 2002. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 21: 2037-2050.
56. Paulmurugan R, Massoud TF, Huang J, Gambhir SS. 2004. Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res 64: 2113-2119.
57. Payne DJ, Holmes DJ, Rosenberg M. 2001a. Delivering novel targets and antibiotics from genomics. Curr Opin Investig Drugs 2: 1028-1034.
58. Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT. 2001b. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov Today 6: 537-544.
59. Projan SJ. 2002. New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr Opin Pharmacol 2: 513-522.
60. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
61. Schmid MB. 1998. Novel approaches to the discovery of antimicrobial agents. Curr Opin Chem Biol 2: 529-534.
62. Schnappinger D, Hillen W. 1996. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol 165: 359-369.
63. Sharma VK, Dean-Nystrom EA. 2003. Detection of enterohemorrhagic Escherichia coli O157:H7 by using a multiplex real-time PCR assay for genes encoding intimin and Shiga toxins. Vet Microbiol 93: 247-260.
64. Spaltmann F, Blunck M, Ziegelbauer K. 1999. Computer-aided target selection-prioritizing targets for antifungal drug discovery. Drug Discov Today 4: 17-26.
65. Stephenson K, Hoch JA. 2002. Two-component and phosphorelay signal-transduction systems as therapeutic targets. Curr Opin Pharmacol 2: 507-512.
66. Stephenson K, Hoch JA. 2004. Developing inhibitors to selectively target two-component and phosphorelay signal transduction systems of pathogenic microorganisms. Curr Med Chem 11: 765-773.
67. Struelens MJ. 1998. The epidemiology of antimicrobial resistance in hospital acquired infections: problems and possible solutions. Br Med J 317: 652-654.
68. Stuber K, Frey J, Burnens AP, Kuhnert P. 2003. Detection of type III secretion genes as a general indicator of bacterial virulence. Mol Cell Probes 17: 25-32.
69. Sun YH, Bakshi S, Chalmers R, Tang CM. 2000. Functional genomics of Neisseria meningitidis pathogenesis. Nature Med 6: 1269-1273.
70. Tanner ME, Vaganay S, van Heijenoort J, Blanot D. 1996. Phosphinate inhibitors of the D-glutamic acid-adding enzyme of peptidoglycan biosynthesis. J Org Chem 61: 1756-1760.
71. Terstappen GC, Reggiani A. 2001. In silico research in drug discovery. Trends Pharmacol Sci 22: 23-26.
72. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
73. Triccas JA, Gicquel B. 2000. Life on the inside: probing Mycobacterium tuberculosis gene expression during infection. Immunol Cell Biol 78: 311-317.
74. Wang G, Clark CG, Rodgers FG. 2002. Detection in Escherichia coli of the genes encoding the major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 Shiga toxin family by multiplex PCR. J Clin Microbiol 40: 3613-3619.
75. Weber W, Anke T, Bross M, Steglich W. 1990. Strobilurin D and strobilurin F: two new cytostatic and antifungal (E)-β -methoxyacrylate antibiotics from Cyphellopsis anomala (1). Planta Med 56: 446-450.
76. Willins DA, Kessler M, Walker SS, Reyes GR, Cottarel G. 2002. Genomics strategies for antifungal drug discovery - from gene discovery to compound screening. Curr Pharm Des 8: 1137-1154.
77. Zambrowicz BP, Sands AT. 2003. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev Drug Discov 2: 38-51.
78. Zitzler E. 1999. Evolutionary Algorithms for Multiobjective Optimization: Methods and Applications. Shaker Verlag: Aachen.